Regeneron Pharmaceuticals (REGN)

Nasdaq · Tarrytown, New York, USA · Founded 1988 · CEO Leonard Schleifer

Valuation summary

$1,086.97 fair value versus $923.34 in the market, a difference of +17.7%. Rated Buy.

Fair value per share$1,086.97
Current share price$923.34
Upside / downside+17.7%
Bear case$792.18
Bull case$1,496.62
Discount rate (WACC)9.6%
Terminal growth2.80%
Market capitalisation$96B
EV / Sales5.0x

About Regeneron Pharmaceuticals

Founded in 1988 by Leonard Schleifer, a neurologist, with George Yancopoulos as chief scientist — both still run the company from Tarrytown, New York. Regeneron's platform technologies, VelocImmune and VelociSuite, generate fully human antibodies quickly and have produced an unusual hit rate. Key products: Eylea for retinal disease, Dupixent for atopic dermatitis and asthma, which is co-developed with Sanofi and is one of the fastest-growing drugs in the world, and Libtayo in oncology. It also runs a large human genetics sequencing programme.

Investment case

  • Dupixent keeps adding indications and is on track to become one of the largest drugs in the industry.
  • The antibody discovery platform has repeatedly produced approved medicines, a rare and hard-to-copy record, most recently Pasatru for the ultra-rare bone disease FOP in August 2026.
  • Substantial net cash and no reliance on external financing.

Key risks

  • Eylea faces aggressive biosimilar competition in the US, and that erosion is already visible in the numbers.
  • Dupixent economics are shared with Sanofi, so Regeneron captures only part of the value, and the expanded October 2026 alliance left Dupixent terms unchanged.
  • Concentration in two products means a single competitive setback moves the whole story.

Recent developments

Revenue by segment

Dupixent collaboration revenue44%
Eylea32%
Libtayo & Other24%

Five-year forecast

RevenueFree cash flow
Year 1$19.6B$4.7B
Year 2$22.8B$5.3B
Year 3$26.0B$5.9B
Year 4$29.1B$6.5B
Year 5$31.8B$6.9B

What the street says

Well regarded scientifically, with the debate centred on how fast Eylea erodes versus how fast Dupixent grows. The October 2026 Sanofi deal, which brings $1B upfront but no better Dupixent economics, disappointed some investors, and a securities suit over a failed melanoma trial is pending.

Comparable companies: VRTX · EW · ISRG · IDXX · ARGX · SNY · ABT · A

Open the interactive model, price chart and sensitivity grid →